Importance Patients who are immunocompromised have increased risk for morbidity and
mortality associated with coronavirus disease 2019 (COVID-19) because they less …

Convalescent plasma (CP) recurs as a frontline treatment in epidemics because it is
available as soon as there are survivors. The COVID-19 pandemic represented the first …

The COVID-19 pandemic is now approaching 2 years old, with more than 440 million people
infected and nearly six million dead worldwide, making it the most significant pandemic …

We compared the performance of SARS-CoV-2 neutralising antibody testing between 12
European laboratories involved in convalescent plasma trials. Raw titres differed almost 100 …

Introduction Immunocompromised patients with B-cell depletion agents are at risk for
persistence and/or severe SARS-COV-2 infection. We describe a case series of 21 COVID …

Convalescent plasma (CP) from patients recovered from COVID-19 is one of the most
studied anti-viral therapies against SARS-COV-2 infection. The aim of this study is to …

Here we describe the case of a 51 years old Italian woman with acute lymphoblastic
leukemia who underwent to hematopoietic stem cell transplantation (HSCT) during SARS …

Since late 2019, the new SARS-CoV-2 virus belonging to the Coronaviridae family has been
responsible for COVID-19 pandemic, a severe acute respiratory syndrome. Several antiviral …

Abstract Coronavirus disease 2019 (COVID-19) convalescent plasma (CovCP) infusions
have been widely used for the treatment of hospitalized patients with COVID-19. The aims of …

The burden of COVID-19 remains unchanged for immunocompromised patients who do not
respond to vaccines. Unfortunately, Omicron sublineages are resistant to monoclonal …